CA
NZ
UK
AU
IND
US
The average realized gold price was $4,211 per ounce, compared with $3,412 a year earlier. Gold production was 11,685 ounces, slightly below 12,428 ounces in the prior-year quarter, andGross Profitrose to $5.0 million from $3.1 million. The company said full-year production is expected to …
Ibotta runs a performanceMarketingplatform that delivers digital promotions for consumer packaged goods brands through a network of retailer, delivery and app publishers. Brands pay only when a campaign results in a verified sale.
Ichor designs, engineers and manufactures critical fluid delivery subsystems and components for semiconductorCapitalequipment.GAAPgross margin was 15.8% and non-GAAP gross margin was 16.0%, up from 4.6% and 5.1% in the third quarter of 2025. Management said the 16% level arrived a quarter ahead of plan, …
CAG Diagnostics recurring revenue rose 11% organically to $967.4 million, with nearly 14% growth internationally and about 9.6% in the U.S. Management said growth wasVolumeled and included about 4% net price. IDEXX VetLab consumables revenue reached $443.2 million, up 15% organically, and reference laboratory …
IRT is a multifamily apartment REIT with a portfolio of 115 operating properties and 33,398 units at quarter end. Rental and other property revenue was $172.0 million, up about 3.0% from $166.9 million a year ago (calculated).
The firm is a global technology research and advisory company that helps clients with sourcing, technologyInvestmentdecisions and the governance of provider relationships, and it has about 1,500 professionals. Management said it pivoted to an AI-centered model roughly two years ago.
Net income attributable to common stockholders was $28.7 million, or $0.99 per diluted share, compared with $28.3 million, or $0.97. Normalized FFO was $50.2 million, or $1.80 per share, up from $1.60. AFFO reached $54.8 million, or $1.96 per share, which is about 14.6% …
The company makes the Inspire system, a hypoglossal nerve stimulation therapy for patients with moderate to severe obstructive sleep apnea. Management attributed the decline mainly to billing and reimbursement uncertainty around the latest Inspire V device and estimated that coding and reimbursement problems cost …
The company still posted a net loss of $0.02 per share, versus net income of $0.01 a year earlier. Net loss was $5.6 million, asDepreciationand amortization jumped to $78.7 million from $30.9 million after the wave of purchases.Transaction Costsadded $3.4 million.
The Irish-incorporated company develops medicines for rare diseases, with a portfolio spanning sleep disorders, epilepsy and cancer. Xywav net sales increased 12% to $483 million after about 425 net patient additions, while Epidiolex sales were $295 million. Management said Epidiolex growth was held back …
Please wait processing your request...